The MEK1/2 Inhibitor ATR-002 (Zapnometinib) Synergistically Potentiates the Antiviral Effect of Direct-Acting Anti-SARS-CoV-2 Drugs

The MEK1/2 Inhibitor ATR-002 (Zapnometinib) Synergistically Potentiates the Antiviral Effect of Direct-Acting Anti-SARS-CoV-2 Drugs

The coronavirus disease 2019 (COVID-19) represents a global public health burden. In addition to vaccination, safe and efficient antiviral treatment strategies to restrict the viral spread within the patient are urgently needed. An alternative approach to a single-drug therapy is the combinatory use...

Full description

Bibliographic Details
Main Authors: André Schreiber, Benjamin Ambrosy, Oliver Planz, Sebastian Schloer, Ursula Rescher, Stephan Ludwig
Format: Article
Language:English
Published: MDPI AG 2022-08-01
Series:Pharmaceutics
Subjects:
SARS-CoV-2
COVID-19
antiviral drug
MEK1/2 inhibitor
ATR-002
drug synergy
Online Access:https://www.mdpi.com/1999-4923/14/9/1776

Internet

https://www.mdpi.com/1999-4923/14/9/1776

Similar Items